There are plenty of ASX 200 blue chip shares to choose from on the local share market for your self-managed super fund (SMSF). But which ones could be buys?
Three that are highly rated right now are listed below. Here's why brokers rate them as buys:
The first ASX 200 blue chip share that could be a buy is Brickworks. It specialises in property, investments, and the manufacture and distribution of building products for the residential and commercial markets.
The team at Bell Potter is tipping Brickworks as a buy. Its analysts believe the company could benefit from interest rate cuts in 2025. They explain:
We see BKW as a high delta exposure to interest rate cuts and by extension a stock to own as we edge closer to the cycle pivot point (Bell Potter's base case for our first cut is 1H CY25). Specifically, we see a scenario unfolding where BKW could realise double digit mark-to-market NTA growth p.a. quite comfortably in coming years through positive revals (i.e. cap rate reversal), ongoing property development and rent reversion (BKW remains ~28% underrented and 50% short-WALE), as well as continued SOL outperformance. This is a growth story we think few ASX-200 industrials can currently match.
Bell Potter currently has a buy rating and $32.00 price target on its shares.
Another ASX 200 blue chip share that could be a top buy for an SMSF is CSL. It is the biotechnology giant behind the CSL Behring, CSL Vifor, and CSL Seqirus businesses.
Goldman Sachs is feeling very upbeat about the company's outlook after a difficult period. As a result, it feels that its shares are undervalued at current levels. It said:
Our Buy recommendation for CSL is driven by (1) Strong growth in the IG market despite the entry of new drugs (anti-FcRn), (2) CSL market share gains in the IG market, Hemophilia, Hereditary Angiodema (HAE) and influenza vaccines, and (3) Gross Margin accretion driven by operational improvements to its cost base. We believe CSL's valuation multiple de-rate is onerous considering the growth outlook, particularly for IG therapies.
Goldman has a buy rating and $318.40 price target CSL's shares.
Finally, Goldman Sachs also sees this wine giant as an ASX 200 blue chip share to buy right now.
It likes the company due to its growing Penfolds business and feels that its shares are "inexpensive" at current levels. It said:
Net net, we remain Buy at A$12.9/sh TP implying 27% TSR. TWE is trading at FY26 P/E of ~15x, which is inexpensive relative to our Consumer coverage. If TWE is able to demonstrate added comfort to the market on its Penfolds channel sell-through and sustained US luxury portfolio growth, we expect the stock to re-rate positively.
Goldman has a buy rating and $12.90 price target on its shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.